Aripiprazole


D2/D3 partial agonist atypical antipsychotic

A piperazinyl-quinolinone partial agonist at D2 and 5-HT1A receptors; the prototype third-generation antipsychotic.

Abstract

Aripiprazole (7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydroquinolin-2(1H)-one; CAS 129722-12-9; molecular formula C23H27Cl2N3O2; molecular weight 448.39) is a piperazinyl-quinolinone D2 partial agonist developed at Otsuka and approved by the FDA in 2002 under the trade name Abilify. Distinct from earlier antipsychotics by partial agonism: D2 affinity is high (Ki approximately 0.34 nM) but intrinsic activity is approximately 30 percent, producing antagonism in regions of high dopaminergic tone (mesolimbic, treating psychosis) and agonism in regions of low tone (mesocortical, mitigating negative symptoms; nigrostriatal, reducing extrapyramidal effects). Additional 5-HT1A partial agonism (Ki approximately 1.7 nM, intrinsic activity approximately 70 percent) and 5-HT2A antagonism complete the profile. The metabolic risk is intermediate (lower than olanzapine or clozapine). Plasma half-life is 75 hours; metabolism is via CYP3A4 and CYP2D6. Approved for schizophrenia, bipolar I disorder, MDD adjunctive, autism-associated irritability, and Tourette syndrome. Long-acting injectable formulations (Abilify Maintena, Aristada) provide monthly administration. Used as the reference D2 partial agonist in mechanism studies.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph